Journal rankings · indicator year 2013
Choose a field to open its ranking, or a journal to find its row in its subfield’s list.
Subfield ranking · 2013
Oncology journal rankings 2013
170 ranked journals · Subfield in Medicine
Oncology has 170 ranked journals in 2013. The median journal has an OJR of 0.97, below the world average of 1.00, down 0.03 on 2012; Q1 starts at OJR 1.54. The top three are CA A Cancer Journal for Clinicians, Cancer Cell, and The Lancet Oncology.
Ranks and citation indicators: 2013. Journal access status and listed APC: source snapshot September 23, 2026.
Journals whose main subfield sits in this category and that published at least 30 citable documents (articles, reviews and conference papers) in 2010–2012, the window the 2013 score is computed on.
The OpenJournalRank Indicator (OJR) is a free, publicly available metric of a journal’s field-normalized citation impact, computed from open OpenAlex citation data. It compares citations to a journal’s papers from the previous three years with the world average for papers of the same subfield, year and type, so 1.00 is the world average and values can be compared across fields. It is computed with the NCI3 method.
The middle OJR among ranked journals in this category: half score higher, half lower. 1.00 is the world average for papers of the same subfield, year and type.
The dot is this category, the solid tick is the median of all ranked journals and the dashed line is the world average.
Share of ranked journals in this category that are fully open access, so every paper is free to read. Hybrid journals, which sell subscriptions and open single papers for a fee, are not counted.
Median list price of the article processing charge, in US dollars, among ranked journals in this category that list a price above zero. Journals with a listed APC of $0 and journals with no known price are left out of this median. The At a glance table below gives a second median that includes the $0 prices.
Subfields of Medicine (42)
- Surgery675
- Pulmonary and Respiratory Medicine266
- Public Health, Environmental and Occupational Health227
- Cardiology and Cardiovascular Medicine218
- Oncology170
- Infectious Diseases162
- Epidemiology157
- Endocrinology, Diabetes and Metabolism132
- Neurology132
- Radiology, Nuclear Medicine and Imaging129
- Physiology120
- Psychiatry and Mental health119
Show all 42 subfields
- Orthopedics and Sports Medicine88
- Dermatology73
- Pediatrics, Perinatology and Child Health73
- Ophthalmology70
- Hematology64
- Rheumatology56
- Obstetrics and Gynecology55
- Nephrology46
- Pharmacology40
- Reproductive Medicine40
- Complementary and alternative medicine39
- Geriatrics and Gerontology36
- Emergency Medicine34
- Otorhinolaryngology33
- Rehabilitation24
- Critical Care and Intensive Care Medicine22
- Pathology and Forensic Medicine22
- Hepatology18
- Genetics17
- Immunology and Allergy17
- Urology11
- Anesthesiology and Pain Medicine10
- Gastroenterology6
- Internal Medicine5
- Family Practice2
- Transplantation2
- Biochemistry1
- Health Informatics1
- Anatomy0
- Microbiology0
170 ranked journals
Filters
Rank is the position by OJR within the list on screen; 1 is the highest. | OJR is field-normalized 3-year citation impact: 1.00 is the world average for papers of the same subfield, year and type, so values compare across fields. The badge is the journal’s quartile in this list. | Citations per paper over a two-year window, counted from OpenAlex. It is not field-normalized, so compare it only between journals of the same field. ▲ or ▼ is the change from 2012. This is OpenJournalRank’s own count, not Clarivate’s Journal Impact Factor. | Citable documents (articles, reviews and conference papers) published in 2010–2012, the window the 2013 OJR is computed on. A journal needs at least 30 to be ranked. | Share of the journal’s 2010–2012 papers that are free to read in any open-access form. The green OA tag next to a title marks a fully open-access journal. | List price of the article processing charge in US dollars. “$0 listed” means the listed price is zero; a dash means no price is listed. | The line is the journal’s OJR from 2004 to 2013. | Compare |
|---|---|---|---|---|---|---|---|
1CA A Cancer Journal for CliniciansOAWiley · United States | 73.88Q1 | 210.23 13.30 up from 2012 | 68 | 100% | $4,330 | ||
2Cancer CellCell Press · Netherlands | 7.42Q1 | 20.03 0.05 down from 2012 | 495 | 100% | $10,400 | ||
3The Lancet OncologyElsevier BV · United Kingdom | 6.24Q1 | 15.89 1.80 up from 2012 | 807 | 16% | $7,280 | ||
4Journal of Clinical OncologyLippincott Williams & Wilkins · United States | 5.55Q1 | 13.09 0.59 down from 2012 | 2,937 | 8% | — | ||
5Nature MedicineNature Portfolio · United States | 5.15Q1 | 12.68 2.27 up from 2012 | 1,433 | 34% | $12,690 | ||
6JNCI Journal of the National Cancer InstituteOxford University Press · United States | 3.99Q1 | 11.52 0.67 up from 2012 | 643 | 50% | $5,436 | ||
7Seminars in Cancer BiologyElsevier BV · United States | 3.69Q1 | 11.09 1.95 up from 2012 | 170 | 30% | $6,060 | ||
8Clinical Cancer ResearchAmerican Association for Cancer Research · United States | 3.51Q1 | 9.78 0.60 up from 2012 | 2,303 | 48% | — | ||
9Clinical Pharmacology & TherapeuticsWiley · United States | 3.08Q1 | 6.39 0.72 up from 2012 | 928 | 23% | $4,410 | ||
10Journal of the National Comprehensive Cancer NetworkNational Comprehensive Cancer | 2.95Q1 | 5.43 2.05 down from 2012 | 280 | 66% | — | ||
11Annals of OncologyElsevier BV · Netherlands | 2.74Q1 | 6.78 0.19 up from 2012 | 1,592 | 99% | $5,080 | ||
12Journal of Mammary Gland Biology and NeoplasiaSpringer Science+Business Media · United States | 2.62Q1 | 5.56 2.16 down from 2012 | 95 | 49% | $4,090 | ||
13CancerWiley · United States | 2.50Q1 | 5.84 0.20 up from 2012 | 2,300 | 67% | $4,790 | ||
14International Journal of CancerWiley · United States | 2.46Q1 | 5.18 1.09 down from 2012 | 1,994 | 72% | $5,030 | ||
15Cancer Treatment ReviewsElsevier BV · United Kingdom | 2.39Q1 | 7.65 1.14 up from 2012 | 317 | 21% | $4,910 | ||
16Molecular Cancer TherapeuticsAmerican Association for Cancer Research · United States | 2.30Q1 | 6.74 0.56 up from 2012 | 874 | 14% | — | ||
17British Journal of CancerSpringer Nature · United Kingdom | 2.26Q1 | 5.97 0.18 down from 2012 | 1,644 | 100% | $5,190 | ||
18The OncologistOAAlphaMed Press · United Kingdom | 2.24Q1 | 5.59 0.13 down from 2012 | 641 | 94% | $3,852 | ||
19European Journal of CancerElsevier BV · United Kingdom | 2.23Q1 | 5.21 0.84 down from 2012 | 1,276 | 14% | $4,270 | ||
20European Journal of EpidemiologySpringer Science+Business Media · Italy | 2.22Q1 | 5.18 0.10 down from 2012 | 313 | 32% | $3,690 | ||
21The Cancer JournalLippincott Williams & Wilkins · United States | 2.17Q1 | 5.12 0.73 up from 2012 | 251 | 32% | — | ||
22Seminars in OncologyElsevier BV · United States | 2.16Q1 | 5.08 0.78 down from 2012 | 253 | 15% | $3,550 | ||
23Journal of Hematology & OncologyOABioMed Central · United Kingdom | 2.16Q1 | 6.28 0.81 up from 2012 | 187 | 100% | $4,990 | ||
24Cancer DiscoveryAmerican Association for Cancer Research · United States | 2.13Q1 | 5.13 0.84 up from 2012 | 520 | 22% | — | ||
25Cancer Epidemiology Biomarkers & PreventionAmerican Association for Cancer Research · United States | 2.09Q1 | 5.13 0.76 down from 2012 | 1,017 | 68% | — | ||
26Cancer Prevention ResearchAmerican Association for Cancer Research · United States | 2.06Q1 | 5.83 0.39 up from 2012 | 640 | 33% | — | ||
27Current Opinion in OncologyLippincott Williams & Wilkins · United Kingdom | 2.01Q1 | 4.97 0.18 down from 2012 | 314 | 15% | — | ||
28Current Treatment Options in OncologySpringer Science+Business Media · United States | 1.93Q1 | 4.27 0.03 up from 2012 | 94 | 27% | $4,890 | ||
29JNCI MonographsOxford University Press · United Kingdom | 1.87Q1 | 2.88 2.11 down from 2012 | 111 | 94% | — | ||
30Journal of Cancer SurvivorshipSpringer Science+Business Media · United States | 1.85Q1 | 4.72 0.30 down from 2012 | 133 | 47% | $4,790 | ||
31Breast Cancer ResearchOABioMed Central · United Kingdom | 1.82Q1 | 5.43 0.98 up from 2012 | 813 | 100% | $4,190 | ||
32Expert Opinion on Investigational DrugsTaylor & Francis · United Kingdom | 1.79Q1 | 4.67 0.19 up from 2012 | 451 | 20% | — | ||
33Diseases of the Colon & RectumLippincott Williams & Wilkins · United States | 1.77Q1 | 4.16 0.12 up from 2012 | 721 | 6% | — | ||
34Cancer ControlOASAGE Publishing · United States | 1.66Q1 | 4.08 1.25 down from 2012 | 90 | 48% | $2,650 | ||
35Cancer Immunology ImmunotherapyOASpringer Science+Business Media · Germany | 1.65Q1 | 4.98 0.62 up from 2012 | 545 | 99% | $4,590 | ||
36Critical Reviews in Oncology/HematologyElsevier BV · Netherlands | 1.63Q1 | 4.42 0.19 down from 2012 | 333 | 19% | $4,190 | ||
37BMC CancerOABioMed Central · United Kingdom | 1.61Q1 | 4.44 0.10 down from 2012 | 1,851 | 100% | $3,390 | ||
38Therapeutic Advances in Medical OncologyOASAGE Publishing · United Kingdom | 1.58Q1 | 4.77 1.30 up from 2012 | 86 | 100% | $2,800 | ||
39Current Oncology ReportsSpringer Science+Business Media · United States | 1.57Q1 | 3.41 0.64 down from 2012 | 206 | 13% | $5,090 | ||
40Journal of ImmunotherapyLippincott Williams & Wilkins · United States | 1.54Q1 | 4.12 0.04 up from 2012 | 215 | 42% | — | ||
41Archives of Pathology & Laboratory MedicineOAAmerican Medical Association · United States | 1.54Q1 | 3.53 0.05 up from 2012 | 677 | 33% | — | ||
42Seminars in Oncology NursingElsevier BV · United States | 1.54Q1 | 2.78 0.19 up from 2012 | 96 | 12% | $3,590 | ||
43Cancer Research and TreatmentOAKorean Cancer Association · South Korea | 1.54Q1 | 4.72 1.93 up from 2012 | 119 | 100% | — | ||
44Cancer MicroenvironmentSpringer Science+Business Media · Netherlands | 1.46Q2 | 4.33 0.39 up from 2012 | 90 | 93% | $3,860 | ||
45Frontiers in OncologyOAFrontiers Media · Switzerland | 1.42Q2 | 3.48 2.71 up from 2012 | 265 | 100% | $3,801 | ||
46Clinical & Experimental MetastasisSpringer Science+Business Media · Netherlands | 1.42Q2 | 3.68 0.50 down from 2012 | 254 | 48% | $5,090 | ||
47Cancer Causes & ControlSpringer Science+Business Media · Netherlands | 1.39Q2 | 3.38 0.60 down from 2012 | 620 | 58% | $3,890 | ||
48Chemotherapy Research and PracticeHindawi Publishing Corporation · Egypt | 1.37Q2 | 3.69 1.77 up from 2012 | 49 | 100% | — | ||
49Psycho-OncologyWiley · United Kingdom | 1.36Q2 | 3.31 0.23 up from 2012 | 596 | 24% | $4,940 | ||
50Journal of Cancer EpidemiologyHindawi Publishing Corporation · United Kingdom | 1.34Q2 | 3.14 0.48 up from 2012 | 46 | 100% | $950 |
Subfields of Medicine, with Oncology highlighted.
- Surgery675
- Pulmonary and Respiratory Medicine266
- Public Health, Environmental and Occupational Health227
- Cardiology and Cardiovascular Medicine218
- Oncology170
- Infectious Diseases162
- Epidemiology157
- Endocrinology, Diabetes and Metabolism132
- Neurology132
- Radiology, Nuclear Medicine and Imaging129
- Physiology120
- Psychiatry and Mental health119
- Orthopedics and Sports Medicine88
- Dermatology73
- Pediatrics, Perinatology and Child Health73
- Ophthalmology70
- Hematology64
- Rheumatology56
- Obstetrics and Gynecology55
- Nephrology46
- Pharmacology40
- Reproductive Medicine40
- Complementary and alternative medicine39
- Geriatrics and Gerontology36
- Emergency Medicine34
- Otorhinolaryngology33
- Rehabilitation24
- Critical Care and Intensive Care Medicine22
- Pathology and Forensic Medicine22
- Hepatology18
- Genetics17
- Immunology and Allergy17
- Urology11
- Anesthesiology and Pain Medicine10
- Gastroenterology6
- Internal Medicine5
- Family Practice2
- Transplantation2
- Biochemistry1
- Health Informatics1
- Anatomy0
- Microbiology0
Journals
Citations made in 2013. Corpus-wide, 76.9% of core-journal articles and reviews published that year have at least one matched reference; the share varies by journal and field.
51 additional Oncology journals with metrics are unranked under this release’s eligibility rules: a journal needs at least 30 citable documents in 2010–2012, at least 80% of them with a subfield, and a positive world-average expectation. Ranks are within the whole category; filters hide rows without re-ranking. OJR excludes self-citations.
At a glance
Indicator year: 2013. Publication window: 2010–2012. How these summaries are calculated
- Ranked journals
- 170
- Window papers (baseline)
- 88,804 +15.3% from indicator year 2010
- Median OJR
- 0.974 -3.6% from indicator year 2010
- Rising journals (2025)
- 20
Window papers are the baseline paper population: citable papers (articles, reviews and conference papers) from 2010–2012 in all journals of the world-average baseline, including non-core journals, counted by each paper’s own subfield. They are not the papers of the ranked journals alone.
| Measure | Year series | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranked journals | 82 | 88 | 96 | 103 | 109 | 120 | 120 | 126 | 127 | 134 | 141 | 150 | 153 | 170 | 179 | 188 | 198 | 213 | 224 | 234 | 238 | 239 | 245 | 245 | 243 | 242 | |
| Window papers (baseline) | 37,821 | 41,430 | 44,340 | 47,392 | 49,058 | 53,111 | 57,002 | 62,106 | 66,087 | 71,283 | 77,009 | 82,075 | 86,189 | 88,804 | 93,912 | 98,660 | 102,921 | 105,891 | 109,984 | 115,044 | 121,890 | 139,666 | 156,942 | 167,602 | 163,907 | 160,807 | |
| Median OJR | 0.55 | 0.62 | 0.70 | 0.799 | 0.805 | 0.831 | 0.85 | 0.90 | 0.94 | 0.93 | 1.010 | 0.95 | 1.006 | 0.974 | 0.972 | 0.967 | 0.832 | 0.84 | 0.82 | 0.79 | 0.829 | 0.830 | 0.77 | 0.750 | 0.73 | 0.748 |
How to read these rankings
- OJR, the OpenJournalRank Indicator
- A field-normalized 3-year citation impact, computed from OpenAlex with the NCI3 method. It divides the citations a journal’s papers received by the world average for papers of the same subfield, year and type, so 1.00 is the world average and 2.00 means twice as many citations as expected. Because it is normalized, it can be compared across fields. Read the methodology
- Quartiles
- Q1 to Q4 split the ranked journals of the list you are viewing into four equal groups by OJR. A journal’s quartile depends on the list: the same journal can be Q1 in its subfield and Q2 among all journals.
- Impact factor (2-year)
- Citations per paper over a two-year window, counted from OpenAlex. It is easy to compare with familiar impact factors but is not field-normalized, so compare it only within a field. It is not Clarivate’s Journal Impact Factor. Why it differs from the Journal Impact Factor
- Rank ranges
- Each rank in the latest year carries a likely range from 1,000 resamples of the journal’s papers. Where two journals’ ranges overlap, the data cannot tell them apart, so treat neighbouring ranks as ties.